Hormone Receptor Positive Breast Cancer Therapeutics
1. Faslodex patent expiration
Treatment: Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy; Treatment of hr-positive, human epidermal growth factor...
FASLODEX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6774122 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(4 years ago) | |
|
US8466139 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(4 years ago) | |
|
US8329680 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(4 years ago) | |
| US7456160 | ASTRAZENECA | Formulation |
Jan, 2021
(5 years ago) | |
| US8466139 | ASTRAZENECA | Formulation |
Jan, 2021
(5 years ago) | |
| US8329680 | ASTRAZENECA | Formulation |
Jan, 2021
(5 years ago) | |
| US6774122 | ASTRAZENECA | Formulation |
Jan, 2021
(5 years ago) | |
|
US7456160 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-126) | Sep 09, 2013 |
| Pediatric Exclusivity(PED) | Mar 09, 2014 |
| M(M-103) | May 17, 2014 |
| M(M-123) | Nov 09, 2015 |
| New Indication(I-725) | Feb 19, 2019 |
| New Indication(I-749) | Aug 25, 2020 |
Drugs and Companies using FULVESTRANT ingredient
Market Authorisation Date: 25 April, 2002
Dosage: SOLUTION
How can I launch a generic of FASLODEX before it's drug patent expiration?
More Information on Dosage
FASLODEX family patents
2. Inluriyo patent expiration
Treatment: Treatment of adults with er-positive, her2-negative esr1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11117902 | ELI LILLY AND CO | NA |
Jul, 2039
(13 years from now) | |
| US10654866 | ELI LILLY AND CO | NA |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2030 |
Drugs and Companies using IMLUNESTRANT TOSYLATE ingredient
NCE-1 date: 25 September, 2029
Market Authorisation Date: 25 September, 2025
Dosage: TABLET
More Information on Dosage
INLURIYO family patents